Compositions and Methods for Determining Cancer Stem Cell Self-Renewal Potential
Researchers at UC San Diego have developed a method for determining the self-renewal potential of CSCs. This technology involves CSC-specific analysis and quantitation of key players (splice variants of proteins and transcripts) in metabolic pathways that are critical for cell survival and self-renewal. The analysis of the cross-talk within cell survival and self-renewal pathways enables the: Determination of the self-renewal potential of cancer stem cells.Determination of the prognosis or malignant potential of cancer from the CSC.Identification of targets for drugs that lower self-renewal potential.Prediction of the susceptibility of a CSC to drug treatment (inhibition of self-renewal).
Patent Number: US20110059448A1
Application Number: US2010821738A
Inventor: JAMIESON, Catriona H. | SCHAIRER, Annelie | GERON, Ifat | DAO, Kim-Hien
Priority Date: 23 Jun 2009
Priority Number: US20110059448A1
Application Date: 23 Jun 2010
Publication Date: 10 Mar 2011
IPC Current: C12Q000168 | C12Q000102
US Class: 435005 | 435006 | 43500614 | 435029
Assignee Applicant: The Regents of the University of California
Title: COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL
Usefulness: COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL
Summary: The methods are used for determining the self-renewal potential of a CSC through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC; identifying a target for a composition or drug that inhibits the self-renewal potential of a CSC; and determining the prognosis or malignant potential of a cancer (all claimed).
Novelty: Determining the self-renewal potential of a cancer stem cell (CSC) by detecting and quantifying B-cell lymphoma-2 (Bcl-2) family protein or its isoform or a transcript encoding Bcl-2 family protein or its isoform in CSCs
生物醫學
DNA /基因工程
State Of Development Validation experiments confirm cell type and context specific deregulation of apoptosis via deregulated expression in the CSC population. In vivo studies on CSC engraftment validate the therapeutic potential of targeting survival pathways and in vitro studies suggest mechanism of action. Intellectual Property Info Pending U.S. patent application 20110059448. Related Materials Related Technologies Additional Technologies by these Inventors Tech ID/UC Case 22170/2009-187-0 Related Cases 2009-187-0, 2012-155-0
美國
